mAb114 Antibody Therapy Description
mAb114 is a human IgG1 MAb targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
mAb114 is a single monoclonal antibody that binds to the core receptor binding domain of the Zaire ebolavirus surface protein, preventing the virus from infecting human cells. It was isolated from the blood of a survivor of the 1995 outbreak of Ebola virus disease in the Democratic Republic of Congo.
mAb114 is a monoclonal antibody therapy that is infused intravenously into patients with Ebola virus disease. mAb114 is a neutralizing antibody, which means It binds to a protein on the surface of the Ebola virus that is required to infect cells. Specifically, mAb114 neutralizes an infection by binding to a region of the Ebola virus envelope glycoprotein that, in the absence of mAb114, would interact with the virus's cell receptor protein.
mAb114 was developed by the Vaccine Research Center with support from the U.S. NIH and the Defense Advanced Projects Agency. A license for mAb114 was obtained by Ridgeback Biotherapeutics LP in 2018 from the NIH.
mAb114 Antibody Therapy Indication
mAb114 is indicated to protect from the Ebola virus. mAb114 has been shown success with lowering the mortality rate from ~70% to about 34%.
mAb114 Antibody Therapy Dosage
mAb114 is administered by IV infusion at dosages of 5, 25, and 50 mg/kg in the clinical trial.
mAb114 Antibody Therapy Updates
May 18, 2020: Vir Biotechnology, Inc. announced it is advancing two clinical development candidates based on the S309 antibody as potential therapeutics for COVID-19, VIR-7831, and VIR-7832, in collaboration with GlaxoSmithKline.
September 6, 2019: Ridgeback Biotherapeutics LP announced that the Food and Drug Administration has recently granted mAb114, an experimental treatment for Ebola, Breakthrough Therapy designation.
August 13, 2019: The first-ever multi-drug randomized control trial aimed at evaluating the safety and efficacy of Ebola Zaire therapeutic medications reported 2 experimental products will continue to be studied. The Pamoja Tulinde Maisha study’s investigational agents were ZMapp, remdesivir, mAb114, and REGN-EB3. Additionally, this DSMD said ‘all future study participants should be randomized to receive either the REGN-EB3 or mAb114 medications.’
December 13, 2018 - Ridgeback Biotherapeutics LP announced that it has entered into a patent license agreement with the NIH, for intellectual property related to the monoclonal antibody mAb114, an experimental treatment for Ebola.
mAb114 Antibody Therapy Clinical Trials
Clinical Trial NCT03719586: Investigational Therapeutics for the Treatment of People With Ebola Virus Disease.
Clinical Trial NCT03478891: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adult.